September 27, 2021 5:32pm

End of the month and Q3 are disruptive

Pre-open indication results: 5 Hits and 0 MISS

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 


The Dow closed UP +71.37 points (+0.21%); the S&P closed DOWN -12.37 points (-0.28%) while the Nasdaq closed DOWN -77.73 points (-0.52%)

 

Henry’omics:

Indexes were divided on Monday as Treasury yields rose and traders braced for the final week of a volatile September.

Investors are monitoring the progress in Washington as lawmakers try to prevent a government shutdown, a default on U.S. debt and the possible collapse of President Joe Biden's sweeping economic agenda. <CNBC>

 

Economic Data Docket: new orders for durable goods waltzed past analyst expectations, gaining 1.8% in August.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Monday opened positive at 18/15, 1 flat and 1 acquired, stayed positive at the mid-day at 19/14, 1 flat and 1 acquired, ending with a positive close of 18/15, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “Q3’s end is coming Thursday. Brace for the final week of September being volatile” … https://www.regmedinvestors.com/articles/12112

 

Pre-open indication results: 5 Hits: <Applied Genetic Technologies (AGTC +$0.01), CRISP Therapeutics (CRSP +$0.83), Global Blood Therapeutics (GBT +$0.65), Editas Medicine (EDIT -$0.87), Biostage (BSTG $0.00)> and 0 MISS>

 

The Biostage (BSTG) Chronicles: “wrongful death law suit, insurance claim denied” … https://www.regmedinvestors.com/articles/12110

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 24

 

Key Metric - volume:

  • Sector volume was LOW with 4 of the 18-upside having higher than the 3-month average volume with Non-Existent volume of 2 of 15-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: wrongful death law suit, insurance claim denied” … https://www.regmedinvestors.com/articles/12110

  • WHAT happened to the usual “pump/promote”?

Monday closed flat with 135 shares traded

Friday closed flat with 62 shares traded, Thursday closed up +$0.06 with 839 shares traded, Wednesday closed down -$0.45 with 3,833 shares traded, Tuesday closed up +$0.25 with 654 shares traded and last Monday closed down -$0.26 to $3.40 with 563 shares traded.

  • WERE BSTG’s Q2 8-K and 10-Q filings AUDITED or UNAUDITED for investors?
  • Will legal fees to defend the terminal death suit going to bankrupt the company now, that costs will not be covered by insurance?
  • The largest issue was NOT providing the documents to the other attorneys as a sanction was put-on and then removed?
  • Should the D&O, company and office and board covered insurances <which were very high> about to jump even higher?

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY +$6.45) - again, Sage Therapeutics (SAGE +$1.44), Regenxbio (RGNX +$1.31), bluebird bio (BLUE +$0.89), CRISPR Therapeutics (CRSP +$0.83), Global Blood Therapeutics (GBT +$0.65), AxoGen (AXGN +$0.41), Sangamo Therapeutics (SGMO (SGMO +$0.20), Adverum Biotechnologies (ADVM +$0.14), Precigen (PGEN +$0.11) to name 10 of the 18 inclining of the 35 covered

Hammered in today’s market:

  • Ultragenyx (RARE -$6.45), BioLife Solutions (BLFS -$2.73), Intellia Therapeutics (NTLA -$1.56) - again, ReNeuron (RENE.L -$1.00), Editas Medicine (EDIT -$0.87) - again, Fate Therapeutics (FATE -$0.49) - again, uniQure NV (QURE -$0.47), Ionis Pharmaceuticals (IONS -$0.33), Solid Biosciences (SLDB -$0.07), Pluristem (PSTI -$0.06) to name 10 of the 15 declining of the 35 covered

Closing flat:

  • 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -1.75% and XBI closed up +1.18%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +1.01 points or +5.69% at 18.76

 

September, the third month of Q3/21:

Monday (9/27) closed positive with 18 advancer, 15 decliners, 1 flat and 1 acquired

Friday closed negative with 4 advancers, 28 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE: Sector stocks sensitive to market flux barely beat as the Nasdaq indexes ended lower on Monday.

In talking to many investors – dull with low volume was the theme of today’s input.

Investors were still mulling implications on-going political antics. It’s going to “bite” and hard!

Sentiment has been capricious and languishing as the sector bounded to the downside.

The stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.